http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 31 Aug 2026 08:09:36 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C250+at+Morgan+Stanley/27001403.html Morgan Stanley analyst Sean Laaman raised the price target on argenx SE (NASDAQ: ARGX) to $1,250.00 (from $1,230.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C250+at+Morgan+Stanley/27001403.html Mon, 31 Aug 2026 08:09:36 -0400 ARGX http://www.streetinsider.com/Intl+Ratings/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C010+at+Kepler+Cheuvreux/26992084.html Kepler Cheuvreux analyst Damien Choplain raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR1,010.00 (from EUR810.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C010+at+Kepler+Cheuvreux/26992084.html Fri, 28 Aug 2026 03:56:34 -0400 ARGX http://www.streetinsider.com/Intl+Ratings/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C010+at+Kepler+Cheuvreux/26992084.html Kepler Cheuvreux analyst Damien Choplain raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR1,010.00 (from EUR810.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C010+at+Kepler+Cheuvreux/26992084.html Fri, 28 Aug 2026 03:56:34 -0400 ARGX http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C010+at+Kepler+Cheuvreux/26992084.html Kepler Cheuvreux analyst Damien Choplain raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR1,010.00 (from EUR810.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C010+at+Kepler+Cheuvreux/26992084.html Fri, 28 Aug 2026 03:56:34 -0400 ARGX http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C010+at+Kepler+Cheuvreux/26992084.html Kepler Cheuvreux analyst Damien Choplain raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR1,010.00 (from EUR810.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C010+at+Kepler+Cheuvreux/26992084.html Fri, 28 Aug 2026 03:56:34 -0400 ARGX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ARGENX+SE+++++++++++++++++For%3A+Aug+27/26990299.html si-local-file:///var/storage/secattach/20260827/26990299.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ARGENX+SE+++++++++++++++++For%3A+Aug+27/26990299.html Thu, 27 Aug 2026 16:20:00 -0400 0QW0 ARGX O.04870500 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ARGENX+SE+++++++++++++++++For%3A+Aug+27/26990299.html si-local-file:///var/storage/secattach/20260827/26990299.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ARGENX+SE+++++++++++++++++For%3A+Aug+27/26990299.html Thu, 27 Aug 2026 16:20:00 -0400 0QW0 ARGX O.04870500 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ARGENX+SE+++++++++++++++++For%3A+Aug+27/26990299.html si-local-file:///var/storage/secattach/20260827/26990299.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ARGENX+SE+++++++++++++++++For%3A+Aug+27/26990299.html Thu, 27 Aug 2026 16:20:00 -0400 0QW0 ARGX O.04870500 http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C415+at+Wells+Fargo/26976938.html Wells Fargo analyst Derek Archila raised the price target on argenx SE (NASDAQ: ARGX) to $1,415.00 (from $1,350.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C415+at+Wells+Fargo/26976938.html Wed, 26 Aug 2026 06:24:51 -0400 ARGX http://www.streetinsider.com/Upgrades/UBS+Upgrades+argenx+SE+%28ARGX%29+to+Buy/26976402.html <p>UBS analyst Xian Deng upgraded argenx SE (NASDAQ: ARGX) from Neutral to Buy with a price target of $1,400.00 (from $960.00).</p><p>The analyst comments: “We view Argenx as a rare, highly successful biotech growth story. The stock has more than tripled in the last 5 years, driven by the successful launch and label expansion of Vyvgart, its flagship drug in rare diseases. Despite strong performance, we think the story is far from over. Argenx has multiple P3 readouts in 2026/27 that could drive this already successful company into the next league. We were previously cautious into the Vyvgart P3 myositis readout http://www.streetinsider.com/Upgrades/UBS+Upgrades+argenx+SE+%28ARGX%29+to+Buy/26976402.html Wed, 26 Aug 2026 03:24:21 -0400 ARGX http://www.streetinsider.com/Analyst+Comments/UBS+Upgrades+argenx+SE+%28ARGX%29+to+Buy/26976402.html <p>UBS analyst Xian Deng upgraded argenx SE (NASDAQ: ARGX) from Neutral to Buy with a price target of $1,400.00 (from $960.00).</p><p>The analyst comments: “We view Argenx as a rare, highly successful biotech growth story. The stock has more than tripled in the last 5 years, driven by the successful launch and label expansion of Vyvgart, its flagship drug in rare diseases. Despite strong performance, we think the story is far from over. Argenx has multiple P3 readouts in 2026/27 that could drive this already successful company into the next league. We were previously cautious into the Vyvgart P3 myositis readout http://www.streetinsider.com/Analyst+Comments/UBS+Upgrades+argenx+SE+%28ARGX%29+to+Buy/26976402.html Wed, 26 Aug 2026 03:24:21 -0400 ARGX http://www.streetinsider.com/Downgrades/Deutsche+Bank+Downgrades+argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+to+Hold/26965562.html (Updated - August 24, 2026 10:28 AM EDT) <p>Deutsche Bank analyst Emmanuel Papadakis downgraded argenx SE (ARGX:BB) (NASDAQ: ARGX) from Buy to Hold.</p><p>The analyst comments "After our myositis/MMN deep-dive early July, ARGX duly read out a positive headline for Vyvgart’s P3 ALKIVIA in the myositis setting during our August vacation, with preliminary details that largely underwrote the assumptions we expressed in that detailed report. Nonetheless, with ARGX up almost 50% from our u/g to Buy in March we cut to Hold; we had lifted our multiple based PT +20% to €900 with July’s deep dive alongside a material increase in our http://www.streetinsider.com/Downgrades/Deutsche+Bank+Downgrades+argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+to+Hold/26965562.html Mon, 24 Aug 2026 10:28:43 -0400 ARGX http://www.streetinsider.com/Downgrades/Deutsche+Bank+Downgrades+argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+to+Hold/26965562.html (Updated - August 24, 2026 10:28 AM EDT) <p>Deutsche Bank analyst Emmanuel Papadakis downgraded argenx SE (ARGX:BB) (NASDAQ: ARGX) from Buy to Hold.</p><p>The analyst comments "After our myositis/MMN deep-dive early July, ARGX duly read out a positive headline for Vyvgart’s P3 ALKIVIA in the myositis setting during our August vacation, with preliminary details that largely underwrote the assumptions we expressed in that detailed report. Nonetheless, with ARGX up almost 50% from our u/g to Buy in March we cut to Hold; we had lifted our multiple based PT +20% to €900 with July’s deep dive alongside a material increase in our http://www.streetinsider.com/Downgrades/Deutsche+Bank+Downgrades+argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+to+Hold/26965562.html Mon, 24 Aug 2026 10:28:43 -0400 ARGX http://www.streetinsider.com/Intl+Ratings/Deutsche+Bank+Downgrades+argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+to+Hold/26965562.html (Updated - August 24, 2026 10:28 AM EDT) <p>Deutsche Bank analyst Emmanuel Papadakis downgraded argenx SE (ARGX:BB) (NASDAQ: ARGX) from Buy to Hold.</p><p>The analyst comments "After our myositis/MMN deep-dive early July, ARGX duly read out a positive headline for Vyvgart’s P3 ALKIVIA in the myositis setting during our August vacation, with preliminary details that largely underwrote the assumptions we expressed in that detailed report. Nonetheless, with ARGX up almost 50% from our u/g to Buy in March we cut to Hold; we had lifted our multiple based PT +20% to €900 with July’s deep dive alongside a material increase in our http://www.streetinsider.com/Intl+Ratings/Deutsche+Bank+Downgrades+argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+to+Hold/26965562.html Mon, 24 Aug 2026 10:28:43 -0400 ARGX http://www.streetinsider.com/Intl+Ratings/Deutsche+Bank+Downgrades+argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+to+Hold/26965562.html (Updated - August 24, 2026 10:28 AM EDT) <p>Deutsche Bank analyst Emmanuel Papadakis downgraded argenx SE (ARGX:BB) (NASDAQ: ARGX) from Buy to Hold.</p><p>The analyst comments "After our myositis/MMN deep-dive early July, ARGX duly read out a positive headline for Vyvgart’s P3 ALKIVIA in the myositis setting during our August vacation, with preliminary details that largely underwrote the assumptions we expressed in that detailed report. Nonetheless, with ARGX up almost 50% from our u/g to Buy in March we cut to Hold; we had lifted our multiple based PT +20% to €900 with July’s deep dive alongside a material increase in our http://www.streetinsider.com/Intl+Ratings/Deutsche+Bank+Downgrades+argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+to+Hold/26965562.html Mon, 24 Aug 2026 10:28:43 -0400 ARGX http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Downgrades+argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+to+Hold/26965562.html (Updated - August 24, 2026 10:28 AM EDT) <p>Deutsche Bank analyst Emmanuel Papadakis downgraded argenx SE (ARGX:BB) (NASDAQ: ARGX) from Buy to Hold.</p><p>The analyst comments "After our myositis/MMN deep-dive early July, ARGX duly read out a positive headline for Vyvgart’s P3 ALKIVIA in the myositis setting during our August vacation, with preliminary details that largely underwrote the assumptions we expressed in that detailed report. Nonetheless, with ARGX up almost 50% from our u/g to Buy in March we cut to Hold; we had lifted our multiple based PT +20% to €900 with July’s deep dive alongside a material increase in our http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Downgrades+argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+to+Hold/26965562.html Mon, 24 Aug 2026 10:28:43 -0400 ARGX http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Downgrades+argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+to+Hold/26965562.html (Updated - August 24, 2026 10:28 AM EDT) <p>Deutsche Bank analyst Emmanuel Papadakis downgraded argenx SE (ARGX:BB) (NASDAQ: ARGX) from Buy to Hold.</p><p>The analyst comments "After our myositis/MMN deep-dive early July, ARGX duly read out a positive headline for Vyvgart’s P3 ALKIVIA in the myositis setting during our August vacation, with preliminary details that largely underwrote the assumptions we expressed in that detailed report. Nonetheless, with ARGX up almost 50% from our u/g to Buy in March we cut to Hold; we had lifted our multiple based PT +20% to €900 with July’s deep dive alongside a material increase in our http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Downgrades+argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+to+Hold/26965562.html Mon, 24 Aug 2026 10:28:43 -0400 ARGX http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C230+at+Morgan+Stanley/26941338.html Morgan Stanley analyst Sean Laaman raised the price target on argenx SE (NASDAQ: ARGX) to $1,230.00 (from $1,200.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C230+at+Morgan+Stanley/26941338.html Tue, 18 Aug 2026 08:54:21 -0400 ARGX http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C100+at+Oppenheimer/26940597.html Oppenheimer analyst Leland Gershell raised the price target on argenx SE (NASDAQ: ARGX) to $1,100.00 (from $1,037.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C100+at+Oppenheimer/26940597.html Tue, 18 Aug 2026 07:44:11 -0400 ARGX http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C100+at+RBC+Capital%2C+%27We+Think+Approval+In+DM+Is+When%2C+Not+If%27/26940554.html <p>RBC Capital analyst Luca Issi raised the price target on argenx SE (NASDAQ: ARGX) to $1,100.00 (from $1,025.00) while maintaining a Outperform rating.</p><p>The analyst commented: "ARGX reported myositis topline data (note) and we just caught up with the team. On IMNM, data was slum dunk given the trial hit the stats convincingly (p=0.0048), the evidence replicates the Phase II (14.8 benefit in TIS) and approval at this point seems very likely given BTD. Commercially, we think uptake could be very rapid given the very first drug to have shown a benefit in Phase III, 20k patients in the US alone http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C100+at+RBC+Capital%2C+%27We+Think+Approval+In+DM+Is+When%2C+Not+If%27/26940554.html Tue, 18 Aug 2026 07:33:54 -0400 ARGX http://www.streetinsider.com/Analyst+Comments/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C100+at+RBC+Capital%2C+%27We+Think+Approval+In+DM+Is+When%2C+Not+If%27/26940554.html <p>RBC Capital analyst Luca Issi raised the price target on argenx SE (NASDAQ: ARGX) to $1,100.00 (from $1,025.00) while maintaining a Outperform rating.</p><p>The analyst commented: "ARGX reported myositis topline data (note) and we just caught up with the team. On IMNM, data was slum dunk given the trial hit the stats convincingly (p=0.0048), the evidence replicates the Phase II (14.8 benefit in TIS) and approval at this point seems very likely given BTD. Commercially, we think uptake could be very rapid given the very first drug to have shown a benefit in Phase III, 20k patients in the US alone http://www.streetinsider.com/Analyst+Comments/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C100+at+RBC+Capital%2C+%27We+Think+Approval+In+DM+Is+When%2C+Not+If%27/26940554.html Tue, 18 Aug 2026 07:33:54 -0400 ARGX http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C202+at+H.C.+Wainwright/26940307.html H.C. Wainwright analyst Douglas Tsao raised the price target on argenx SE (NASDAQ: ARGX) to $1,202.00 (from $940.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C202+at+H.C.+Wainwright/26940307.html Tue, 18 Aug 2026 06:50:28 -0400 ARGX http://www.streetinsider.com/Intl+Ratings/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C000+at+Barclays/26939718.html Barclays analyst Charles Pitman-King raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR1,000.00 (from EUR980.00) while maintaining a Overweight rating. http://www.streetinsider.com/Intl+Ratings/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C000+at+Barclays/26939718.html Tue, 18 Aug 2026 05:05:20 -0400 ARGX http://www.streetinsider.com/Intl+Ratings/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C000+at+Barclays/26939718.html Barclays analyst Charles Pitman-King raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR1,000.00 (from EUR980.00) while maintaining a Overweight rating. http://www.streetinsider.com/Intl+Ratings/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C000+at+Barclays/26939718.html Tue, 18 Aug 2026 05:05:20 -0400 ARGX http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C000+at+Barclays/26939718.html Barclays analyst Charles Pitman-King raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR1,000.00 (from EUR980.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%3ABB%29+%28ARGX%29+PT+Raised+to+EUR1%2C000+at+Barclays/26939718.html Tue, 18 Aug 2026 05:05:20 -0400 ARGX